Kirk, Allan D <br/><br/>
Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin.  [electronic resource] 

 -  Transplantation  Oct 2005 
 - 1051-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0041-1337 
<br/><br/><label>Standard No.: </label>10.1097/01.tp.0000174341.49741.8f  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--pharmacology<br/>Chemokines--genetics<br/>Creatine--blood<br/>Female<br/>Graft Rejection--metabolism<br/>Guanidines--pharmacology<br/>Humans<br/>Immunosuppressive Agents--pharmacology<br/>Kidney--cytology<br/>Kidney Transplantation--immunology<br/>Lymph Nodes--cytology<br/>Lymphocyte Count<br/>Lymphocyte Depletion<br/>Male<br/>Middle Aged<br/>T-Lymphocytes--drug effects<br/>Transcription, Genetic<br/>Transplantation Tolerance--drug effects